<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336306">
  <stage>Registered</stage>
  <submitdate>2/12/2010</submitdate>
  <approvaldate>6/12/2010</approvaldate>
  <actrnumber>ACTRN12610001072000</actrnumber>
  <trial_identification>
    <studytitle>Prevention of bronchiectasis in infants with cystic fibrosis</studytitle>
    <scientifictitle>A Phase 3 multi-centre randomised placebo-controlled study of azithromycin in the primary prevention of radiologically-defined bronchiectasis in infants with cystic fibrosis</scientifictitle>
    <utrn>U1111-1118-3843</utrn>
    <trialacronym>COMBAT CF</trialacronym>
    <secondaryid>STICK10K0</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>bronchiectasis in cystic fibrosis</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>azithromycin liquid preparation given by oral administration 10 mg/kg three times a week from 3 months of age until  3 years of age</interventions>
    <comparator>inert liquid preparation, identical in taste and colour, given by oral administration three times a week from 3 months of age until  3 years of age</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion of children with radiologically-defined bronchiectasis</outcome>
      <timepoint>three years of age</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>extent and severity of bronchiectasis</outcome>
      <timepoint>three years of age</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>CF-related quality of life</outcome>
      <timepoint>three years of age</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>time to first pulmonary exacerbation</outcome>
      <timepoint>3 years of age</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>proportion of participants experiencing a pulmonary exacerbation</outcome>
      <timepoint>3 years of age</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>number of courses of inhaled or oral antibiotics</outcome>
      <timepoint>3 years of age</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>number of days of inhaled antibiotics</outcome>
      <timepoint>3 years of age</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>incidence of hospitalizations/Accident &amp; Emergency visitsfor acute respiratory exacerbations</outcome>
      <timepoint>3 years of age</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>number of days of hospitalization and number of days of intravenous antibiotics for acute respiratory exacerbations</outcome>
      <timepoint>3 years of age</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>volume of trapped gas at age 3 years assessed using a low dose volumetric computed tomography scan</outcome>
      <timepoint>3 years of age</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Body mass index</outcome>
      <timepoint>3 years of age</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Children of either sex with a diagnosis of CF following detection via New Born Screening (NBS);
2. Participants who, in the opinion of the Investigator, are able to comply with the protocol for its duration;
3. Written informed consent signed and dated by parent/legal guardian according to local regulations</inclusivecriteria>
    <inclusiveminage>6</inclusiveminage>
    <inclusiveminagetype>Weeks</inclusiveminagetype>
    <inclusivemaxage>6</inclusivemaxage>
    <inclusivemaxagetype>Months</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Born &lt;30 weeks gestation;
2. Prolonged mechanical ventilation in the first 3 months of life;
3. Participation in another randomized controlled trial within the 3 months preceding inclusion in this study;
4. A significant medical disease or condition other than CF that is likely to interfere with the childs ability to complete the entire protocol;
5. Previous major surgery except for meconium ileus;
6. Macrolide hypersensitivity</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Participants are enrolled following confirmation of cystic fibrosis via new born screening. Randomisation by IWRS.</concealment>
    <sequence>Block randomization stratified by study site</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/01/2012</anticipatedstartdate>
    <actualstartdate>15/07/2012</actualstartdate>
    <anticipatedenddate>31/05/2017</anticipatedenddate>
    <actualenddate>3/05/2017</actualenddate>
    <samplesize>130</samplesize>
    <actualsamplesize>130</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>31/05/2021</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,WA,VIC</recruitmentstate>
    <hospital>Princess Margaret Hospital - Subiaco</hospital>
    <hospital>The Royal Childrens Hospital - Parkville</hospital>
    <hospital>Lady Cilento Children's Hospital - South Brisbane</hospital>
    <hospital>The Children's Hospital at Westmead - Westmead</hospital>
    <hospital>Sydney Children's Hospital - Randwick</hospital>
    <hospital>Womens and Childrens Hospital - North Adelaide</hospital>
    <postcode>6008</postcode>
    <postcode>4101</postcode>
    <postcode>4029</postcode>
    <postcode>2145</postcode>
    <postcode>2031</postcode>
    <postcode>3052</postcode>
    <postcode>3168</postcode>
    <postcode>5006</postcode>
    <postcode>6008 - Subiaco</postcode>
    <postcode>3052 - Parkville</postcode>
    <postcode>4101 - South Brisbane</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>2031 - Randwick</postcode>
    <postcode>5006 - North Adelaide</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Telethon Kids Institute</primarysponsorname>
    <primarysponsoraddress>100 Roberts Rd
Subiaco WA 6008</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Cystic Fibrosis Foundation Therapeutics Inc</fundingname>
      <fundingaddress>Grants and Contracts office
6931 Arlington Rd
Bethesda Maryland 20814</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other</sponsortype>
      <sponsorname>Queensland Children's Medical Research Institute</sponsorname>
      <sponsoraddress>Level 4, Foundation Building
Royal Children's Hospital
Herston Rd, Herston Qld 4029</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The general aim of this project is to conduct a randomized, double-blind, placebo, placebo-controlled clinical trial of azithromycin to determine whether treatment from infancy is safe and will prevent the onset of bronchiectasis. One hundred and thirty infants will be recruited from CF clinics in Australia and New Zealand and treated from 3 months to three years of age. The primary outcome will be the proportion with radiologically-defined bronchiectasis at 3 years of age. Safety and mechanistic evaluations will also be undertaken.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Princess Margaret Hospital for Children Human Ethics Committee</ethicname>
      <ethicaddress>Roberts Road
Subiaco WA 6008</ethicaddress>
      <ethicapprovaldate>15/04/2010</ethicapprovaldate>
      <hrec>1795/EP</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Professor Stephen Stick</name>
      <address>Department of Respiratory Medicine
Princess Margaret Hospital for Children
Ropberts Rd
Subiaco WA 6008</address>
      <phone>+61893408830</phone>
      <fax>+61893408181</fax>
      <email>stephen.stick@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Nat Eiffler</name>
      <address>Telethon Kids Institute
100 Roberts Rd
SUBIACO WA 6008</address>
      <phone>+61 8 94897814</phone>
      <fax>+61 7 3636 5578</fax>
      <email>nat.eiffler@telethonkids.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Nat Eiffler</name>
      <address>Telethon Kids Institute
100 Roberts Rd
SUBIACO WA 6008</address>
      <phone>+61 8 94897814</phone>
      <fax>+61 7 3636 5578</fax>
      <email>nat.eiffler@telethonkids.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Stephen Stick</name>
      <address>Department of Respiratory Medicine
Princess Margaret Hospital for Children
Roberts Rd
Subiaco WA 6008</address>
      <phone>+61 8 9340 8830</phone>
      <fax>+61 8 9340 8181</fax>
      <email>stephen.stick@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>